What development phase is BUFLOMEDIL in?

BUFLOMEDIL is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

BUFLOMEDIL

FDA-approved withdrawn Small molecule Quality 5/100

At a glance

Generic name	BUFLOMEDIL
Drug class	buflomedil
Target	Voltage-dependent calcium channel gamma-1 subunit, 3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase, Alpha-1A adrenergic receptor
Modality	Small molecule
Therapeutic area	Pain
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Optimization of Treatment in Patients With Severe Peripheral Ischemia (Fontaine Stage IIb) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

BUFLOMEDIL CI brief — competitive landscape report
BUFLOMEDIL updates RSS · CI watch RSS